- Home
- CSAN vs KNSA Comparison
CSAN vs KNSA Comparison
Compare CSAN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSAN | KNSA |
|---|---|---|
| Founded | 1936 | 2015 |
| Country | Brazil | United Kingdom |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.5B |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CSAN | KNSA |
|---|---|---|
| Price | $4.42 | $46.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.75 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 2.4M | 565.9K |
| Earning Date | 05-15-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $321.51 | $38.01 |
| Revenue Next Year | $3.57 | $17.42 |
| P/E Ratio | ★ N/A | $63.27 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $3.72 | $19.42 |
| 52 Week High | $6.25 | $50.03 |
Technical Indicators
Market Signals| Indicator | CSAN | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 51.17 |
| Support Level | $4.17 | $39.96 |
| Resistance Level | $4.74 | $48.14 |
| Average True Range (ATR) | 0.17 | 1.83 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 87.41 | 45.20 |
Price Performance
Historical ComparisonAbout CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.